No Data
No Data
Express News | Lionco Pharmaceutical Group: The wholly-owned subsidiary has received the clinical trial approval notice for Acetazolamide sustained release capsules.
2025 First Quarter Report
Lionco Pharmaceutical Group (603669.SH) announced its first-quarter performance, with a net loss attributable to the parent company of 18.62 million yuan.
Lionco Pharmaceutical Group (603669.SH) disclosed the first quarter report for 2025, in which the company achieved a revenue of 501...
Express News | Innovative Drugs and CRO Concept drive up the market, with multiple stocks including Jinkai Biotechnology reaching their limit-up.
2024 ANNUAL REPORT
2024 Annual Report Summary